Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 55Neoplasm Metastasis 17Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasms 14Pancreatic Neoplasms 11Uveal Melanoma 10Prostatic Neoplasms 10Leukemia, Myeloid, Acute 9Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Myelodysplastic Syndromes 7Lymphoma 7Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Recurrence 5Myeloproliferative Disorders 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Glioblastoma 5Urinary Bladder Neoplasms 4Ovarian Neoplasms 4

Interventions

PROSTVAC 1Nivolumab 1Leukapheresis 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Hormone-Sensitive Prostate Cancer × Ipilimumab × Clear all
NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed
19 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡